Invivyd stock falls as investors await VYD2311 data
Published on 09/03/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Invivyd Inc. stock (ISIN US46186M1080, ticker IVVD) is trading well below 1 dollar on NASDAQ as of early September 2026, reflecting a sharp year-to-date decline from levels above 2 dollars while investors focus on upcoming clinical data for the antibody candidate VYD2311 and the company’s latest quarterly figures.
Mixed Q2 2026 results frame Invivyd’s risk profile
According to market data compiled by MarketBeat, Invivyd reported its second-quarter 2026 earnings on August 13, 2026. Revenue for Q2 2026 came in at USD 14.29 million, compared with analyst estimates of USD 14.40 million, implying a small revenue shortfall of USD 0.11 million against consensus expectations.
On the bottom line, the same Q2 2026 release shows earnings per share of minus USD 0.14, while the average analyst estimate stood at minus USD 0.11 per share. This represents an EPS miss of USD 0.03 per share, underscoring that, at least in the latest quarter, operating performance lagged the expectations built into consensus models.
The MarketBeat overview also aggregates annual figures, listing trailing twelve-month sales of USD 53.43 million and a net income of minus USD 52.49 million, translating into a net margin of roughly minus 183.90 percent over that period. While these annual numbers are historical context rather than a fresh quarter, they highlight that Invivyd remains firmly in loss-making territory even as it seeks to grow revenues with its infectious-disease antibody portfolio.
Stock price under pressure ahead of VYD2311 data
Per an article on ad-hoc-news.de titled Invivyd stock falls as VYD2311 data nears, Invivyd shares were quoted at USD 0.83 on September 2, 2026, after a 12.77 percent slide on that trading day. The same source cites a market capitalization of USD 245.54 million and a trading volume of 8.33 million shares as of September 2, 2026, making clear that the stock’s sharp move occurred on substantial turnover.
The MarketBeat page referenced above points out that Invivyd’s stock started 2026 at a price of USD 2.47 per share. Using that start-of-year value, the source calculates that the share price has decreased by about 67.0 percent year-to-date to a recent level around USD 0.81 as of early September 2026. For investors, this quantified drawdown illustrates how much downside the stock has already experienced while the market waits for clearer evidence that the pipeline can offset ongoing losses.
Additional market data relayed in a stock list on Yahoo Finance, which includes Invivyd in a biotechnology peer overview, shows the company’s market capitalization at approximately USD 236.99 million with a contemporaneous quote near USD 0.80 as of September 2, 2026. This aligns broadly with the MarketBeat and ad-hoc-news.de figures and confirms that Invivyd remains a small-cap biotechnology issuer with a sub-1-dollar share price.
DACH angle via European-listed financial products
While Invivyd itself is listed on NASDAQ in the United States, European investors encounter related biotechnology and healthcare exposure through financial products quoted on DACH-region exchanges. For example, a Marketscreener page for Israel Discount Bank-linked instruments on Deutsche Boerse shows a product trading at 86.00 euros as of September 3, 2026 on Deutsche Boerse AG, with a modest negative change of 0.58 percent versus the previous day. This type of listing illustrates how European capital markets package sector exposure, including biotechnology, into structured or bank-issued instruments that can be traded in Frankfurt and other German venues.
Separately, an ETF such as the Invesco US Enhanced Equity UCITS ETF EUR is shown by Marketscreener trading on Boerse Stuttgart on September 3, 2026. While not specific to Invivyd, such cross-border products allow German and broader DACH-region investors to participate in US small- and mid-cap equities, including biotech names like Invivyd, without purchasing the NASDAQ listing directly.
From a positioning standpoint, this means that sentiment towards US biotechnology names can bleed into DACH-listed instruments and vice versa. When a small-cap US biotech like Invivyd trades near the lower end of its yearly range, as current sub-1-dollar prices suggest, structured products and sector ETFs that hold or reference similar names may also reflect higher volatility or cautious investor appetite.
More background on Invivyd stock
For readers who want additional context on Invivyd’s NASDAQ listing and recent trading pattern, the following resources provide quote data and corporate information.
Pipeline focus: VYD2311 in infectious disease
The ad-hoc-news.de article mentioned above places special emphasis on VYD2311, an investigational monoclonal antibody candidate that Invivyd is developing for the prevention and treatment of respiratory viral infections. As of September 2, 2026, the piece notes that upcoming VYD2311 data are a key catalyst for the share price, because positive clinical results could strengthen the revenue outlook beyond the modest USD 14.29 million achieved in Q2 2026.
As is typical in early-stage biotechnology, the VYD2311 program has yet to generate commercial sales, meaning that its contribution is currently limited to development-stage value rather than reported revenue. Nonetheless, if forthcoming trial readouts demonstrate compelling efficacy and safety, Invivyd would be better positioned to negotiate partnerships or pursue regulatory pathways that could expand its addressable market and reduce the long-term gap between revenue and net losses.
For retail investors, VYD2311 is therefore one of the main reasons to watch Invivyd despite the negative net margin highlighted by MarketBeat. The Q2 2026 figures tell a story of a company that can bring in tens of millions of dollars in sales over twelve months but still loses a comparable amount of money, making future pipeline success a central factor in any long-term investment thesis.
Stock valuation and upcoming earnings date
With a Q2 2026 revenue base of USD 14.29 million and a trailing twelve-month net loss of about USD 52.49 million, Invivyd’s valuation in the USD 236.99 million to USD 245.54 million range as of early September 2026 implies a price-to-sales multiple between roughly 4 and 5 on recent annual revenue, depending on the exact market-cap figure used. This is not unusually high for small-cap biotechnology names, but given the severe net margin and the 67 percent year-to-date share-price decline, it indicates that the market has already repriced the stock downward to reflect execution risk while still assigning some option value to the pipeline.
Both MarketBeat and the ad-hoc-news.de article note that the next expected earnings date for Invivyd is November 5, 2026. That Q3 2026 report will give investors another opportunity to assess whether revenue growth is accelerating, whether losses are stabilizing, and how the company is financing continued R&D efforts around VYD2311 and other antibody candidates.
Heading into that event, the stock’s sub-1-dollar price level carries practical implications: exchange rules on NASDAQ often draw attention to issuers whose shares trade for extended periods below 1 dollar, and while no specific compliance action is stated in the sources at hand, prolonged weakness can lead companies to consider measures such as reverse stock splits to maintain listing standards.
Invivyd’s antibody platform and commercial prospects
Beyond VYD2311, Invivyd’s broader business model centers on designing monoclonal antibodies that can provide prophylactic or therapeutic protection against viral pathogens, with an emphasis on respiratory infections. This platform approach aims to generate a pipeline of candidates that can be updated or tailored as viral strains evolve, potentially offering more flexible protection than traditional vaccines in certain patient populations.
In practical terms, that means the company’s long-term revenue prospects depend on its ability to translate clinical trial success into approved products and reimbursement agreements. The Q2 2026 revenue of USD 14.29 million suggests that Invivyd already has some revenue streams, possibly from early access arrangements or legacy products, but those revenues are not yet sufficient to absorb the costs of R&D, manufacturing scale-up and corporate overheads, as seen in the negative net margin.
For investors evaluating Invivyd stock today, the key question is whether pipeline progress and potential partnerships can lift quarterly revenue figures well above the recent USD 14.29 million level over the next few years, while gradually narrowing losses. The upcoming November 5, 2026 earnings date and any interim trial updates on VYD2311 are thus crucial checkpoints in assessing whether the company can change the trajectory visible in the current numbers.
Closing view: sub-1-dollar price reflects high risk
As of September 2, 2026, Invivyd stock traded at USD 0.83 on NASDAQ, within a market-capitalization range of roughly USD 236.99 million to USD 245.54 million based on data from MarketBeat, Yahoo Finance and ad-hoc-news.de. The year-to-date decline of about 67 percent from a January 2026 price of USD 2.47 per share underscores that the market has significantly discounted the stock while it waits for clearer signs of sustainable revenue growth and pipeline success.
For retail investors, the combination of a mixed Q2 2026 report, deeply negative net margins and a pending data readout for VYD2311 explains why Invivyd shares trade below 1 dollar despite ongoing activity in its antibody pipeline. The next few months, culminating in the expected November 5, 2026 earnings report, will show whether the company can use pipeline momentum to stabilize its financial profile and justify a higher trading range.
Invivyd at a glance
- Company: Invivyd Inc.
- ISIN: US46186M1080
- Ticker: IVVD
- Trading venue: NASDAQ
- Price (as of September 2, 2026): 0.83 USD
- Market capitalization: 245.54 million USD (as of September 2, 2026)
- Sector / Industry: Biotechnology
- Index membership: NASDAQ biotechnology universe
- Next earnings date: November 5, 2026
